On December 30th, the three major indexes of A-shares, , collectively opened higher, and as of the noon close, the Shanghai Composite Index rose 0.61% to 3092.50 points, the Shenzhen Component Index rose 0.35% to 11034.89 points, and the ChiNext Index rose 0.30%. Reported at 2356.47 points.
According to the statistics of Giant Finance, on December 29, biological drugs (159839) led the rise in ETF funds on the market, with an increase of 2.56%. The top-ranked biological drugs 30 (159859) and AH innovative drugs (159748) rose by 2.42% and 2.39% respectively. On the whole, most of them are biopharmaceutical and innovative drug ETFs.
In terms of decline, the education ETF (513360) had the largest decline on the 29th, with a decline of 4.71%. None of the remaining ETFs fell more than 3%. The top-ranked real estate ETF (512200) and Bay Area ETF (512970) fell by 2.45% and 2.43% respectively.
From the perspective of transaction amount, on the 29th the largest transaction amount was 300ETF (510300), with a transaction amount of 2.826 billion yuan. The transaction volume of other ETFs did not exceed 2 billion yuan. The top-ranked HSI technology (513180) and 50ETF (510050) had turnover of 1.739 billion and 1.714 billion yuan respectively.
In terms of capital flow, the largest net purchase amount on the 29th was China A50 (563,000), with a net purchase amount of 527 million yuan on that day. Then there are ZZ1000 (159633), Huaxia 300 (510330), and HS300ETF (510310) with a net subscription amount of more than 400 million yuan, and the subscription amounts are 459, 438, and 411 million yuan, respectively.
In terms of capital outflows, 50ETF (510050) had the largest net redemption amount on the 29th, with a redemption amount of 628 million yuan, and then GEM (159915) had a redemption amount of more than 200 million yuan; Less than 200 million yuan, the redemption amount is relatively small.
Among the increase of ETF funds on the market yesterday, the number of biological drugs, innovative drugs and ETF accounted for a large proportion. As of November 28, about 14.456 million people over the age of 80 in China have completed enhanced immunization, accounting for about 40% of the population over the age of 80. With the regulation and precision of epidemic prevention and control, in order to further increase the vaccination rate of the elderly, on the basis of the first dose of enhanced immunization, the country has recently given the elderly population aged 60 and above and those with serious underlying diseases Promote the second dose of booster immunization for people with high risk of infection and those with weakened immunity. Vaccination may be indispensable in life in the future, and biomedical companies that are at the forefront of epidemic development may usher in better development.
This article comes from Giant Finance
-
-
-
-
-
-
-
-
-
-